Cargando…

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a risk factor for mortality in patients with lung cancer. Nintedanib has been known to slow down the decline of lung function and reduce IPF exacerbation. We aimed to explore the feasibility of adding nintedanib to chemotherapy for non-small cell lu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makiguchi, Tomonori, Tanaka, Hisashi, Okudera, Koichi, Taima, Kageaki, Tasaka, Sadatomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183406/ https://www.ncbi.nlm.nih.gov/pubmed/37197621 http://dx.doi.org/10.21037/tlcr-22-699

Ejemplares similares

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study
por: Fukushima, Takashi, et al.
Publicado: (2022)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
por: Shiratori, Toshihiro, et al.
Publicado: (2020)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2021)

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2022)

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series
por: Ishioka, Yoshiko, et al.
Publicado: (2022)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2017)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
por: Nakamura, Yume, et al.
Publicado: (2023)

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia
por: Tabe, Chiori, et al.
Publicado: (2022)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report
por: Baba, Keisuke, et al.
Publicado: (2019)

Emergency Radiotherapy for Spinal Cord Compression due to Bone Sarcoidosis
por: Tanaka, Yoshihito, et al.
Publicado: (2017)

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Hisashi, et al.
Publicado: (2018)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
por: Yoon, Hee-Young, et al.
Publicado: (2018)

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
por: Corte, Tamera, et al.
Publicado: (2015)

Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
por: Rodríguez-Portal, José Antonio
Publicado: (2017)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
por: Richeldi, Luca, et al.
Publicado: (2020)

Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil
por: Pereira, Carlos Alberto de Castro, et al.
Publicado: (2019)

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
por: Wollin, Lutz, et al.
Publicado: (2015)

Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
por: Tomioka, Hiromi, et al.
Publicado: (2017)

Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
por: Hajari Case, Amy, et al.
Publicado: (2017)

Effects of Nintedanib on Quantitative Lung Fibrosis Score in Idiopathic Pulmonary Fibrosis
por: Lancaster, Lisa, et al.
Publicado: (2020)

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis
por: Inomata, Minoru, et al.
Publicado: (2015)

Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
por: Ryerson, Christopher J., et al.
Publicado: (2019)

Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
por: Oda, Keishi, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis
por: Shimomura, Iwao, et al.
Publicado: (2018)

Left ventricular dysfunction in an idiopathic pulmonary fibrosis patient on nintedanib
por: Imai, Ryosuke, et al.
Publicado: (2020)

Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis
por: Fukunaga, Kentaro, et al.
Publicado: (2018)

Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis
por: Nishiyama, Osamu, et al.
Publicado: (2021)

Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice
por: Fletcher, Sophie V., et al.
Publicado: (2018)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib
por: Bonella, Francesco, et al.
Publicado: (2015)

Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
por: Lehtonen, Siri T., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_9m91fbsufkrjb83te3legbd88l